Q2 sales rise 17% and EBITDA margin expands to 27.1%

Management guided margin improvementCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹2469.30

prior close

₹2481.90

announcement price

In-mkt

timing

Nifty Midcap 150market-0.9%+1.9% vs market

Pharmaceuticals peers, median of 173sector-0.8%+1.8% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0-0.9+1.9-0.8+1.8

Next day

+0.5+0.3+0.2-0.8+1.3

+0.4+1.3-0.9-0.5+0.9

+2.9+2.9-0.1+0.3+2.6

+1.6+4.9-3.3+1.3+0.3

+2.9pendingpending+1.3+1.6

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma reported Q2 FY27 revenue of Rs 4,338 crore, up 17.3%, EBITDA of Rs 1,175 crore, up 27.2%, and a 27.1% margin, 210 basis points higher year on year. Profit after tax rose 37.7% to Rs 716 crore. International revenue grew 33% to Rs 680 crore, but consumer healthcare remained weak. Management retained FY27 margin guidance of 25.5%-26.5% and expects single-digit consumer growth.

Likely market impact

Strong earnings and margin gains support sentiment, though weak consumer growth and higher working capital remain near-term concerns.